24 results
S-3ASR
EX-4.6
MDGL
Madrigal Pharmaceuticals Inc
7 May 24
Automatic shelf registration
4:06pm
the meanings assigned to them in this Article and include the plural as well as the singular and the masculine gender shall include the feminine
424B5
MDGL
Madrigal Pharmaceuticals Inc
20 Mar 24
Prospectus supplement for primary offering
4:06pm
by at least one stage with no worsening of the NAFLD activity score. Fibrosis improvement and NASH resolution were consistent regardless of age, gender, type
424B5
MDGL
Madrigal Pharmaceuticals Inc
18 Mar 24
Prospectus supplement for primary offering
4:08pm
with no worsening of the NAFLD activity score. Fibrosis improvement and NASH resolution were consistent regardless of age, gender, type 2 diabetes status
8-K
EX-99.1
MDGL
Madrigal Pharmaceuticals Inc
14 Mar 24
Regulation FD Disclosure
6:47pm
stage with no worsening of the NAFLD activity score. Fibrosis improvement and NASH resolution were consistent regardless of age, gender, type 2
S-3ASR
EX-4.10
9tf7ujbq
1 Jun 21
Automatic shelf registration
7:00am
8-K
EX-99.1
lhzx4487r7z74om3bs
3 Jun 13
Synta Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3 Trial of Ganetespib in Second-Line Non-Small Cell Lung Cancer
12:00am